Trial Profile
A Phase II, Multicentre, Double-blind, Parallel Group 8 Week Study to Assess the Efficacy and Safety of Two Doses of CNS-242 in Lowering Serum Uric Acid (SUA) and Preventing Gout Attacks in Gout Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs CNS 242 (Primary)
- Indications Gout
- Focus Therapeutic Use
- Sponsors Nippon Suisan Kaisha
- 26 Jul 2020 Status changed from recruiting to completed.
- 21 Jan 2016 New trial record